1.
Clinical characteristics of 162 patients
| Characteristics | Case No. (%) |
| TACE, transarterial chemoembolization; OXA, oxaliplatin; 5-Fu, 5-fluorouracil; CF, calcium folinate. | |
| Gender | |
| Male | 110 (67.9) |
| Female | 52 (32.1) |
| Age at first TACE (year) | |
| Median | 60 |
| Range | 26–83 |
| Primary location | |
| Right side | 33 (20.4) |
| Left side | 129 (79.6) |
| Primary tumor grade | |
| Poor | 22 (13.6) |
| Well to moderate | 124 (76.5) |
| Unknown | 16 (9.9) |
| Time of liver metastases | |
| Synchronous | 125 (77.2) |
| Metachronous | 37 (22.8) |
| Genetic condition | |
| KRAS mutation | 24 (14.8) |
| KRAS wild type | 51 (31.5) |
| Unknown | 87 (53.7) |
| Extrahepatic metastasis | |
| Present | 91 (56.2) |
| Absent | 71 (43.8) |
| Combination with other local treatment | |
| Yes | 34 (21.0) |
| No | 128 (79.0) |
| Resection of primary cancer | |
| No | 30 (18.5) |
| Palliative | 74 (45.7) |
| Radical | 58 (35.8) |
| Infusion agents | |
| OXA+5-Fu+CF | 140 (86.4) |
| OXA+raltitrexed | 22 (13.6) |